NCT06952465View on ClinicalTrials.gov

A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis

Active, not recruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

January 24, 2025

Primary Completion Date

November 30, 2031

Study Completion Date

November 30, 2031

Conditions
Psoriasis
Interventions
DRUG

Deucravacitinib

As per product label

BIOLOGICAL

Any biologic treatment for psoriasis

According to the product label

Trial Locations (2)

171-0021

Local Institution, Tokyo

Unknown

Medical Data Vision, Inc, Tokyo

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06952465 - A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis | Biotech Hunter | Biotech Hunter